8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 5, 2026·SEC
Lifecore Biomedical, Inc.(LFCR)Earnings, Financials & Key Ratios
LFCR•NASDAQ
$4.96
Price updated Jun 30, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryContract development and manufacturing services
AboutLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.Show more
- Revenue$129M+0.5%
- EBITDA-$9M-992.2%
- Net Income-$39M-422.3%
- EPS (Diluted)-1.27-484.8%
- Gross Margin31.27%-4.2%
- EBITDA Margin-7.15%-987.1%
- Operating Margin-13.38%-94.1%
- Net Margin-30.04%-420.8%
- ROE-612.08%-280.5%
LFCR Price & Volume
Lifecore Biomedical, Inc. (LFCR) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Strategic CDMO Pivot
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and operational insolvency
Key Thesis Takeaways
- Lifecore Biomedical faces a precarious fundamental outlook as it struggles to transition its business model, evidenced by a 34.0% revenue contraction in 2026Q3 and persistent bottom-line losses.
- The company's high fixed-cost structure and significant capital intensity, with CapEx/Revenue ratios reaching 17.8% in 2024Q3, continue to erode shareholder equity.
- Investors should monitor the company's ability to improve utilization rates within its $125.5M net PPE base, as current liquidity constraints and a debt-to-equity ratio of 7.23 suggest significant insolvency risk.
Verdict Logic
the company's inability to achieve consistent profitability, highlighted by a -64.6% net margin in 2026Q3, combined with a precarious liquidity profile, warrants extreme caution.
LFCR Growth Metrics
Lifecore Biomedical, Inc. (LFCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-13.34%
5 Years-4.24%
3 Years5.02%
TTM3.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM30.72%
Return on Capital
10 Years-4.01%
5 Years-6.64%
3 Years-8.73%
Last Year-8.13%
LFCR Recent Earnings
Lifecore Biomedical, Inc. (LFCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (73%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.43-79.2%
$0.24
Rev
—
$31M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.16+40.7%
$0.27
Rev
$35M+6.1%
$33M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.29+3.3%
$0.30
Rev
$31M+17.5%
$26M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.10-11.1%
$0.09
Rev
$36M+44.3%
$25M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.43vs $0.24-79.2% | —vs $31M |
| Q2 2026 | Mar 16, 2026 | $0.16vs $0.27+40.7% | $35Mvs $33M+6.1% |
| Q4 2025 | Nov 6, 2025 | $0.29vs $0.30+3.3% | $31Mvs $26M+17.5% |
| Q3 2025 | Aug 7, 2025 | $0.10vs $0.09-11.1% | $36Mvs $25M+44.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Lifecore Biomedical, Inc. (LFCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.96 | $186.05M | -3.91 | 0.47% | -30.04% | -612.08% | — | |
| $25.09 | $986.92M | 156.81 | 3.63% | 1.27% | 1.31% | — | |
| $77.18 | $9.15B | 30.15 | 37.55% | 23.13% | 126.27% | — | |
| $28.70 | $1.45B | -119.58 | 14.88% | -0.83% | -0.95% | — | |
| $15.48 | $1.76B | -12.69 | 8.28% | -25.66% | -50.82% | — | |
| $350.06 | $10.11B | -25.97 | -100% | — | -43.02% | — |
Compare LFCR vs Peers
Lifecore Biomedical, Inc. (LFCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LFCR SEC Filings & Documents
Lifecore Biomedical, Inc. (LFCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when LFCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LFCR Frequently Asked Questions
Lifecore Biomedical, Inc. (LFCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Lifecore Biomedical, Inc.'s revenue?
Lifecore Biomedical, Inc. (LFCR) reported $135.2M in revenue for fiscal year 2025. This represents a 5306% increase from $2.5M in 1996.
How fast is Lifecore Biomedical, Inc. growing?
Lifecore Biomedical, Inc. (LFCR) grew revenue by 0.5% over the past year. Growth has been modest.
Is LFCR profitable?
Lifecore Biomedical, Inc. (LFCR) reported a net loss of $34.1M for fiscal year 2025.
Dividend & Returns
What is LFCR's return on equity?
Lifecore Biomedical, Inc. (LFCR) has a return on equity (ROE) of -612.1%. Negative ROE indicates the company is unprofitable.
What is Lifecore Biomedical, Inc.'s free cash flow?
Lifecore Biomedical, Inc. (LFCR) generated $10.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.